SAVA trade ideas
Cassava | Tomorrow - scheduled end of phase IIb | Jackpot?Is NASDAQ:SAVA about to blow up soon? The phase IIb will be most likely done by tomorrow whereby the analysis and evaluation of the results is scheduled for May. So there might be one last pullback before the stock will pulverize the last highs (in case the results are positive!). As a consequence of that I will look for good entries to ride the stock to at least 20$ per share :).
Cassava | Back in the game - giant bull flag!NASDAQ:SAVA has stopped it's decline at the 3$ floor and is now back in the giant bull flag.
Cassava | Giant bull flag | no time to panic!NASDAQ:SAVA it's not the time to panic now :). Just wait for the release of the phase IIb data which might blow up the flag in a sudden.
Cassava Science | Run for Alzheimer | Breakout soon?The price of NASDAQ:SAVA is forming a triangle whereby this formation is about to end very soon. Everyone is waiting for the results of the phase IIb study which will be reported in the mid of 2020. So the question is when the stock is going to break out of the low volatility phase. The first target for the upper side is 11$ which might be reached before the publication of the phase IIb results.
Cassava Sciences, Inc.ready for next bull run Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
SAVA bullish flag setting upSAVA bullish flag is setting up. This will take SAVA to the next level 16-20 level for consolidation.
Cassava Science | Run for Alzheimer | Upcoming breakout?The stock NASDAQ:SAVA is consolidating in a triangle and shows relative strength in the past few days. It might happen soon, that the stock will break through the upper boundary of the triangle which will lead the way towards 11$ and later also 15$.
Buy the dip in SAVA based on strong Alzheimer's trial dataCassava Sciences (SAVA) just got some positive clinical trial data on their Alzheimer’s drug. The result caused one analyst firm to upgrade SAVA’s price target from $3.00 per share to $6.00 per share. SAVA’s got a 9.4/10 analyst summary score, with most analysts rating the stock a “buy.” I entered SAVA Friday morning at $2.16 per share. It’s already up almost 100% from its share price last month, but I think it could continue its run next week.
SAVA - Above MA's Possible 15% TargetCassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
SHORT INTEREST
1.64M 08/30/19
P/E Current
-2.07
P/E Ratio (with extraordinary items)
-5.00
Average Recommendation: BUY
Average Target Price: 3.00
SAVAI hope the patter follows and we get news soon! Waiting to see it repeat the previous two spikes.
